Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization

Acta Obstetricia et Gynecologica Scandinavica

Volumn 88, Issue 5, 2009, Pages 563-568

  Kumbak, Banu ^a,c   Kahraman, Semra ^b  

^a YEDITEPE UNIVERSITY   (Turkey)

^b MEMORIAL HOSPITAL   (Turkey)

^c NONE   (Turkey)

Author keywords

Body mass index; In vitro fertilization; Metformin; Polycystic ovary syndrome

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GINERA; GONADORELIN AGONIST; METFORMIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; FOLLITROPIN; GONADORELIN; INSULIN; LUTEINIZING HORMONE; PROSTAGLANDIN E2;

ABORTION; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ESTROGEN BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN SECRETING CELL; HUMAN; IMPLANTATION; INFERTILITY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MENSTRUAL IRREGULARITY; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STIMULATION; SUPPLEMENTATION; BLOOD; CASE CONTROL STUDY; DRUG ANTAGONISM; EMBRYO TRANSFER; FEMALE INFERTILITY; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; METABOLISM; METHODOLOGY; NIDATION; OVULATION INDUCTION; PREGNANCY; TREATMENT OUTCOME; TURKEY (REPUBLIC);

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN; DINOPROSTONE; EMBRYO IMPLANTATION; EMBRYO TRANSFER; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INSULIN; INSULIN RESISTANCE; LUTEINIZING HORMONE; METFORMIN; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TURKEY;

EID: 65649106260     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340902835919     Document Type: Article

References (38)

1. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 1987;65:499-507.
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-82.
3. Rotterdam ESHRE/ASRM-sponsored Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
4. Utiger RD. Insulin and the polycystic ovary syndrome. N Engl J Med. 1996;335:657-8.
5. Franks S, Gharani N, McCarthy M. Genetic abnormalities in polycystic ovary syndrome. Ann Endocrinol. 1999;60:131-3.
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774-800.
7. Frank S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol. 1989;31:87-120.
8. Nestler JE. Polycystic ovary syndrome: a disorder for the generalist. Fertil Steril. 1998;70:811-2.
9. Bailey CJ, Turner RC. Metformin. N Eng J Med. 1996;334: 574-9.
10. Pryor PR, Liu SC, Clark AE, Yang J, Holman GD, Tosh D. Chronic insulin effects on insulin signalling and GLUT4 endocytosis are reversed by metformin. Biochem J. 2000;348: 83-91.
11. Legro RS, Myers E. Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Hum Reprod. 2004;19:1697-704.
12. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-74.
13. Velazquez EM, Mendoza S, Hamer T, Saso F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647-54.
14. Caliskan E, Kilic T, Bodur H, Zeteroglu S. The frequency of metabolic syndrome in women with polycystic ovaries at reproductive age and comparison of different diagnostic criteria for metabolic syndrome. J Turkish-German Gynecol Assoc. 2007;8:402-7.
15. Dale PO, Tanbo T, Vaaler S, Abyholm T Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril. 1992;58:487-91.
16. Meirow D, Yossepowitch O, Rösler A, Brzezinski A, Schenker JG, Laufer N, et al. Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Hum Reprod. 1995;10:1951-6.
17. Acién P, Quereda F, Matalĺin P, Villarroya E, López-Fernandez JA, Acién M, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril. 1999;72: 32-0.
18. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108-16.
19. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikai-nen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998;69:691-6.
20. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab. 1997;82:4075-9.
21. Checa MA, Requena A, Salvador C, Tur R, Callejo J, Espinos JJ, et al. Reproductive Endocrinology Interest Group of the Spanish Society of Fertility. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update. 2005;11:375-90.
22. Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuccu R. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol Reprod Biol. 2005;123:204-11.
23. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol. 2007;157:669-76.
24. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod. 2007;22:2967-73.
25. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505-22.
26. Nestler JE. Metformin in the treatment of infertility in PCOS: an alternative perspective. Fertil Steril. 2008;90: 14-6.
27. Stadtmauer LA, Wong BC, Oehninger S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome - beyond ovulation induction. Hum Reprod. 2002;17:3016-26.
28. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006;332:1485-1489.
29. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551-66.
30. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril. 2001;75:505-9.
31. Kjøtrød SB, von During V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome: a prospective, randomized, double blind study. Hum Reprod. 2004;19:1315-22.
32. Doldi N, Persico P, Di Sebastiano F, Marsiglio E, Ferrari A. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecol Endocrinol. 2006;22:235-8.
33. Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006;21:1416-25.
34. Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod. 2006;21:1387-99.
35. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2007;13:527-37.
36. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:524-9.
37. Khattab S, Mohsen IA, Foutouh IA, Ramadan A, Moaz M, Al-Inany H. Metformin reduces abortion in pregnant women with PCOS. Gynecol Endocrinol. 2006;22:680-.
38. Thatcher SS, Jackson EM. Pregnancy outcome in infertile patients with PCOS who were treated with metformin. Fertil Steril. 2006;85:1002-9.